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1. Introduction
1.1. Herbal medicines in the 21st century
Herbs and herb-derived medicines have played a crucial role in health and disease man‐
agement  for  many centuries.  Many ancient  civilizations  show documented evidence  for
the use of herbs in the treatment of different ailments; as was seen with Mesopotamian,
Indian  ayurveda,  ancient  traditional  Chinese  medicine  and Greek  unani  medicine  [1-5].
In  Africa,  knowledge  of  traditional  medicine  as  part  of  wholistic  system,  was  passed
through generations by oral communication and indigenous practices [6].  The global de‐
mand for herbal medicinal products has increased significantly in recent years. It is esti‐
mated  that,  the  world’s  population  will  be  more  than  7.5  billion  in  the  next  10  to  15
years.  This  increase in population will  occur mostly in the southern hemisphere,  where
approximately  80%  of  the  population  still  relies  on  a  traditional  system  of  medicine
based on herbal drugs for primary healthcare [7].
Use of plants for medicinal purposes is as old as human civilization [8] and continuous ef‐
forts [8-17] are being made towards its improvement. About 200,000 natural products of
plant origin are known and many more are being identified from higher plants and microor‐
ganisms [18-21]. Some plant-based drugs have been used for centuries and for some like car‐
diac glycosides, there is no alternative conventional medicine. Therefore, medicinal plants
and their bioactive molecules are always in demand and are a central point of research. As a
result, there is a recent [22] surge in the demand for herbal medicine.
To date, herbs have remained useful not only as remedy for different diseases that affect hu‐
mans and animals, but also as good starting points for the discovery of bioactive molecules
for drug development. The scientific exploitation of herbs used ethnomedicinally for pain
relief, wound healing and abolishing fevers has resulted in the identification of a wide range
of compounds that have been developed as new therapies for cancer, hypertension, diabetes
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and as anti-infectives [23]. The ealriest report of the toxicity of herbs originated from Galen,
a Greek pharmacist and physician who showed that herbs do not contain only medicinally
beneficial constituents, but may also be constituted with harmful substances. [24].
By 2003 in the United States alone, over 1500 herbal products sold were nutraceuticals
which are exempt from extensive preclinical efficacy and toxicity testing by the U.S. Food
and Drug Administration [25]. This has led to increased concerns about potential harmful
effect of these products, which has resulted in efforts to globally harmonize standards of
toxicity testing methods that can be used for herbal medicine toxicological characterization
including tests for acute high-dose exposure effects, chronic low-dose toxicity tests and spe‐
cific cellular, organ and system-based toxicity assays. This chapter reviews some of these
tests and their applications. Recent biotechnological advancements have rapidly evolved
toxicity test methods at molecular and sub cellular levels including next generation sequenc‐
ing and computer-based modeling and simulation tools which have been used to predict the
potential toxicity of novel drug candidates and in some cases, herbal medicine toxicities
which may arise from herbs administered alone or concomitantly with other herbs and/or
drugs. However, challenges still exist for testing herbal medicines in this exciting field and
these will also be discussed.
2. Toxicity of herbs
Despite the growing market demand for herbal medicines, there are still concerns associated
with not only their use, but their safety. Less than 10% of herbal products in the world mar‐
ket are truly standardized to known active components and strict quality control measures
are not always diligently adhered to [26]. For majority of these products in use, very little is
known about their active and/or toxic constituents. In many countries including the U.S,
herbal medicines are not subjected to the same regulatory standards as orthodox drugs in
terms of efficacy and safety. This raises concern on their safety and implications for their use
as medicines. Toxicity testing can reveal some of the risks that may be associated with use of
herbs, therefore avoiding potential harmful effects when used as medicine.
In addition, many plants produce toxic secondary metabolites as natural defence from ad‐
verse conditions. In some toxicologically and medicinally relevant plant species like Digitalis
purpurea, Hyoscyamus niger, Atropa belladonna, Physostigma venenosum, Podophyllum peltatum
and Solanum nigrum, these toxic substances are not distinguished from therapeutically active
ingredients. Being stationary autotrophs, plants have evolved different means of adaptation
to challenging environments and co-existence with herbivores and pathogenic microorgan‐
isms. Thus, they synthesize an array of metabolites characterized as ‘phytoanticipins‘ or as
general ‘phytoprotectants‘ that are stored in specialized cellular compartments and released
in response to specific environmental stimuli like damage due to herbivores, pathogens or
nutrient depletion [27]. Some of the phytochemicals produced by plants against herbivorous
insects also end up being harmful to humans, because highly conserved biological similari‐
ties are shared between both taxa as seen in most pathways involving protein, nucleic acid,
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carbohydrate and lipid metabolism [28]. Human neurochemicals, often with similar biologi‐
cal functions are also reportedly present in insects [28]. These incude signalling molecules,
neuropeptides, hormones and neurotransmitters [29-32]; whose functions can be mimicked
or antagonized by phytochemicals like alkaloids, flavonoids, terpenoids and saponins. Eco‐
logically, a good number of alkaloids serve as feeding deterrents via agonistic or agonistic
activity on neurotransmitter systems [33]. Similarly, some lipid soluble terpenes have shown
inhibitory properties against mammalian cholinesterase [34], whilst some interact with the
GABAergic system in vertebrates [35]. In addition to these, saponins are potent surfactants
that can disrupt lipid-rich cellular membranes of human erythrocytes and microorganisms
which explains the potent antimicrobial properties of this group of phytochemicals [36]. Ar‐
istolochic acid, a nitrophenanthrene carboxylic acid in Aristolochia species and present in
some other botanicals has also been identified as a phytochemical toxicant implicated in the
development of nephropathies and carcinogenesis [37].
Another implication in the toxicity of certain herbs is the presence of toxic minerals and
heavy metals like mercury, arsenic, lead and cadmium [38]. Lead and mercury can cause se‐
rious neurological impaiment when a herbal medicinal product contaminated with these
metals is ingested. As shown in Table 1, the presence of high levels of arsenic in kelp sea‐
weed may result in toxicosis in some patients [39].
3. Goals of toxicity testing of herbal drugs
The primary aim of toxicological assessment of any herbal medicine is to identify adverse
effects and to determine limits of exposure level at which such effects occur. Two important
factors which are taken into consideration in evaluating the safety of any herbal drug are the
nature and significance of the adverse effect and in addition, the exposure level where the
effect is observed. Toxicity testing can reveal some of the risks that may be associated with
use of herbs especially in sensitive populations.
An equally important  objective of  toxicity testing is  the detection of  toxic  plant  extracts
or compounds derived thereof in the early (pre-clinical) and late (clinical) stages of drug
discovery  and  development  from  plant  sources.  This  will  facilitate  the  identification  of
toxicants  which can be  discarded or  modified during the  process  and create  an  oppor‐
tuinity  for  extensive  evaluation  of  safer,  promising  alternatives  [54].  For  certain  com‐
pounds,  modifications  such  as  dosage  reduction,  chemical  group  or  structural
adjustments may improve their tolerability.
3.1. Pre-clinical toxicity testing of herbs
This covers a range of toxicity tests done in non-human experimental models before con‐
ducting clinical tests for toxic effects in humans. Generally these tests are classified into non-
animal tests and animal studies. Crude extracts or purified compounds obtained by
fractionation of the medicinal herb can be evaluated in these tests.
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Common name Plant source/parts used Intended indications Potential toxicity
Ginseng Panax ginseng roots Relieves stress, promotes mental
and physical activity
Central nervous system
stimulation, hypertension,
skin eruptions [40]
St. John’s wort Hypericum perforatum
aerial parts
Antidepressant, mood stabilizer Highly potent cytochrome
P450 enzyme inducer
which affects drug
metabolism. Also causes
hepatotoxicity and
nephrotoxicity in
pregnancy and lactation
[41]
Kava kava Piper methysticum roots Sedative, anxiolytic Hepatotoxic, cytochrome
P450 enzyme inhibitor [42]
Ginkgo Ginkgo biloba leaves Impotence, vertigo, circulatory
disorders, improves mental
alertness
Gastric irritability,
spontaeneous bleeding
[43]
Danshen Salvia miltiorrhiza exterior
taproot
Angina pectoris,
antihyperlipidemic, ischemic stroke
Bleeding, anticoagulant
effects [44]
Hawthorn Crataegus oxycantha
Flowers, roots, berries
Mild to moderate congestive heart
failure
Cardiac arrythmias,
lowered blood pressure
[45]
Comfrey Symphytum officinale
leaves
Anti inflammatory, antidiarrhoel
and treatment of thrombophlebitis
Hepatotoxicity,
carcinogenicity [46]
Licorice Glycyrrhiza glabra roots Antiulcer, anti inflammatory,
antihypertensive
Hypokalemic myopathy,
pseudoaldosteronism,
thrombocytopenia [47]
Chaparral, creosote
bush
Larrea tridentata leaves
and twigs
Blood thinner, weight loss,
antioxidant, anticancer, anti
arthritis
Carcinogenic, nephrotoxic,
hepatotoxic [48]
Mistletoe Phoradendron spp.,
Viscum album leaves and
young twigs
Digestive aid, heart tonic, sedative Hypotension, seizures [49]
Squill Urginea maritima bulbs Anti-arthritic, bronchial
expectorant
Symptoms resembling
digitalis toxicity [50]
Kelp (seaweed) Liminaria digitata Metabolic tonic, thyroid tonic, anti
inflammatory
Arsenic poisoning,
Hyperthyroidism [39]
Ma-huang Ephedra Promotes weight loss, mental and
physical alertness
Cardiotoxicity,
thyrotoxicosis, seizures [51]
Senna Senna occidentalis seeds Laxative Skeletal and cardiac muscle
degeneration,
hepatotoxicity,
neurotoxicity [52]
Aloe Aloe vera leaves Wound healing, laxative Cytogenetic toxicity [53]
Table 1. Potential toxic effects associated with some common herbal medicines marketed for different indications
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3.2. Cell-based cytotoxicity tests
Cytotoxicity  assays  (CTAs)  are  performed  to  predict  potential  toxicity,  using  cultured
cells which may be normal or transformed cells. These tests normally involve short term
exposure of cultured cells to test substances, to detect how basal or specialized cell func‐
tions may be affected by the substance,  prior  to  performing safety studies  in whole or‐
ganisms. It can also provide insight towards the carcinogenic and genotoxic dispositions
of herb-derived compounds and extracts. The ability of a plant extract to inhibit cellular
growth and viability can also be ascertained as an indication of  its  toxicity.  Assessment
parameters for cytotoxic effects include inhibition of cell proliferation, cell viability mark‐
ers  (metabolic  and  membrane),  morphologic  and  intracellular  differentiation  markers
[55]. In conducting CTAs, it is important to critically consider factors such as cell culture
systems and methods which affect test outcomes. For example, some cell types maybe in‐
compatible with the solvent used to prepare test solutions. Many plant extracts and com‐
pounds  are  non-polar  and prepared as  solutions  in  dimethylsulfoxide  (DMSO)  prior  to
CTAs. DMSO has been reported to be cytotoxic at certain concentrations [56] and this ef‐
fect varies between cell types. Therefore, it is often necessary to pre-determine the maxi‐
mum tolerable solvent concentration in CTAs especially during validatory stages,  and a
control using the carrier solvent alone must be used in the CTA.
CTAs are indispensible tools for medium and high throughput screens of different phyto‐
chemicals simultaneously, over wide concentration ranges. In addition, they have significant
impact in the implementation of the three R’s namely; the reduction of number of animals
used, refinement of animal test models and replacement of animal in research.
As a herbal product may display cytotoxic effects only against specific cell types, it is impor‐
tant to consider the selection of a wide range of cell types for testing including normal cells
of primary origin (usually from rodents), and permanent cell lines; provided they are of
high quality and are reproducible over time [57].
CTAs which employ rodent cell lines like the mouse fibroblast cell line BALB/c 3T3 and
the Syrian Hamster Embryo cells (SHE, pH 6.7 and pH 7) are robust models for the pre‐
diction of genotoxicity and carcinogenity. The tests have been shown to be highly predic‐
tive,  as  inoculation  of  transformed  cells  into  x-ray  irradiated  mice  induces
tumorigenicity.  Furthermore,  there  are  no  limitations  with  specific  classes  of  chemicals
and formulations that can be tested with these assays as it has been reported to be plau‐
sible in the assessment of nanoparticles [58]. Although the applicability of these assays in
testing  complex  mixtures  like  herbal  products  is  often  hindered  by  non-availability  of
sufficient evidence in this regard, it is still useful in predicting their toxic effects so long
it is makes sufficient contact with the cells [59].
In the BALB/c 3T3 assay, foci scoringis based on the level of malignant transformation, with
type III classified as malignantly transformed, according to a previous classification used for
cytotoxicity assays involving C3H10T1/2 cells [61]
Screening of Herbal Medicines for Potential Toxicities
http://dx.doi.org/10.5772/54493
67
Figure 1. Examples of normal and transformed SHE cells. Plates A, B, C show normal colonies of cells organized in
monolayers with no criss-crossing. Plates D, E, F show morphologically transformed colonies comprising stacked cells
that are randomly oriented, three-dimensional and criss-crossed throughout; basophilic staining is usually darker.
Magnification ×125 [60]
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Figure 2. Type I foci: small, non invasive BALB/c 3T3 cells with weak basophilic staining. Under each picture in the
catalogue, the characteristics are described as basophilic (B), spindle-shaped (S), multilayer (M), random orientation
(R), invasive (I) and were evaluated as absent (−), weak (+/−) present (+), or strong (++). Magnification ×50 [62]
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 Figure 3. Type II foci: densely packed multi-layered cells, some cells pile up and are criss-crossed. Magnification ×50 [62]
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Figure 4. Type III foci: Malignantly transformed colony of morphologically different spindle-shaped cells. Cells are densely
multi-layered and criss-crossed. Cells are randomly oriented and grow invasively at foci edge. Magnification ×50 [62]
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3.3. Herbal toxicokinetics
Herbal toxicokinetics deals with the prediction of toxicity due to pharmacokinetic disposi‐
tion of an herb, or purified xenobiotics derived from it, due to genetics or from potential
herb-drug interactions [63] Testing usually begins with assays using human liver microso‐
mal Cytochrome P450 isoforms to identify early enough, metabolites which are known to
cause toxicological modulation at any level of cellular organization. Modulation of Cyto‐
chrome P450 has great significance as this largely affects drug biotransformation to active
or inactive forms. For a drug that is dependent on these enzymes for inactivation via conju‐
gation to chemical polar groups prior to elimination, any herb that induces these enzymes
would lead to rapid inactivation and clearance of such a drug. Converesly, a herbal medi‐
cine that inhibits enzyme activity will lead to high concentrations of a drug whose inactiva‐
tion relies on the inhibited enzyme. From findings in a recent survey [64], potential adverse
drug herb interactions were observed in 40 % of patients receiving conventional therapy
and taking a herbal product. Clinically significant drug-herb interactions may occur when
an herb interacts with metabolism of a co-administered drug and either reduces its efficacy
due to decreased formation of an active metabolite or increases its toxicity due to reduced
metabolic  elimination.  The latter  type of  interaction potentially  predisposes human con‐
sumers to adverse reactions or toxic drug effects, especially if the drug has a narrow thera‐
peutic  range.  This  is  important  because,  approximately  73  %  of  all  known  drugs  are
metabolized hepatically by mixed function oxidation reactions, catalyzed by Cytochrome
P450 enzymes [65]. Of all its isoforms, CYP3A4, CYP2C9, CYP2C19, CYP1A2 and CYP2D6
are implicated in over 80 % of oxidative drug reactions and are highly subject to inhibition
owing to their broad specificity for structurally diverse substrates [66]. Some herbs, notably
St. John's Wort (Hypericum perforatum), ginkgo (Ginkgo biloba), ginseng (Panax ginseng), kava
(Piper methysticum) and garlic (Allium sativum) reportedly show significant interaction with
some co-administered drugs by modulation of Cytochrome P450 [67]. In order to predict
clinically significant effects that can occur when a herbal product inhibits or induces these
enzymes, in vitro metabolic data can be used to correlate metabolic disposition of a test sub‐
stance in vivo [68].
From the early 1990s onwards, new techniques for generating as much information as possi‐
ble from one experiment were developed including DNA sequencing, microarrays to study
gene expression, protein and metabolite profiling [69]. Further structure-activity relation‐
ship of metabolites or pure compounds can be extrapolated from computer-based models
and simulation studies. Thereafter, pattern databases of tissue/organ response to drugs
which allows for the parallel sequencing of all the relevant genes, measurement of genome
transcription, protein expression and quantitation of metabolites produced by direct or indi‐
rect actions of the expressed protein. A final screening category for the compound or metab‐
olite utilizes an integrative system biology approach; comprising databases of metabolic
pathways, genes, regulatory networks and protein interactions [69].
Despite the high efficiency of these techniques, no single approach is sufficient to predict
toxicokinetics in silico and harnessing the different assays will be effective in predicting met‐
abolic fate of the test molecule in humans.
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3.4. Toxicogenomic screening tools
Herbal toxicogenomics is a collective term that refers to the combination of toxicology with
different ‘–omics’ tools that measure the potential toxic outcomes of interactions of the herb‐
al extract or compounds at sub molecular (epigenomics, transcriptomics), molecular (proteo‐
mics), cellular, tissue and organ (metabonomics) levels [70]. It is aimed at elucidating
molecular mechanisms involved in the expression of toxicity, and to derive molecular pat‐
terns (i.e. molecular biomarkers) that predict toxicity or the individual susceptibility to it.
There are three major aspects within this field as outlined below:
DNA microarrays: These are carried out using specially designed microarrays. They usually
provide the most information, providing not only clear prediction of cellular response to
chemical toxicants, but also mechanisms through which such toxicity is elicited [71]. For an
herbal mixture with a diversity of chemical entities, the data obtained cannot usually be ex‐
trapolated to that of data libraries of existing chemical compounds.
Proteomics: This high throughput screening tool is applied in protein identification. It is a
sequential process of peptide separation and profiling, followed by mass spectrometry and
NMR detection. Based on the assumption that a chemically related group of xenobiotics ex‐
hibit specific patterns of protein expression, only purified phytochemicals with known
chemical structures can have their protein expression profiles correlated to existing databas‐
es of those of xenobiotics. The use of proteomics has been considered more advantageous
than microarrays which assess gene expression, because they measure proteins which are
closer to toxicology endpoints, as not all genes are translated to proteins and expressed pro‐
teins are liable to structural changes post-translation [72].
Metabonomics: This is an aspect of toxicity evaluation, performed through the large scale
analysis of metabolic profiles of metabolic enzymes and metabolite composition resulting
from the action of chemical stressors.  This can be a very efficient approach as it  can be
applied in  in  vitro  metabolic  profiling,  in  animal  toxicity  tests  for  promising lead selec‐
tion and in  humans during clinical  stages  of  safety  testing for  the  development  of  bio‐
markers of safety [73].
3.5. High throughput next generation sequencing
Molecular studies have witnessed rapid developments since DNA was first sequenced in
1997 [74] to the creation of large volumes of DNA sequences at unprecedented speed; also
referred to as next generation sequencing (NGS). Apart from its application in personalized
medicine, it has also been applied in the creation of large genetic databases of plants, which
can serve in the identification of potentially toxic plants, or those that may contain allergens.
For example if functional gene transcriptomes present in Aristolochia species are found
present in another specie under investigation, it is likely that such a specie may contain aris‐
tolochic acid. NGS technology has already been applied in unravelling the genome of Ging‐
ko [75] and holds potential for biomarking toxicity in the 21st century.
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3.6. Animal tests
The whole animal is usually presumed to be closely correlated to human toxicity as the sys‐
tem incorporates pharmacokinetic (absorption, distribution, metabolism) disposition of the
test substance when administered by a route similar to its intended use. It also takes into
consideration, other physiological events in an organism that influence toxicity. While cell-
based assays measure is predictive of potential toxicity, the whole animal experiment meas‐
ures the critical toxicity of a test substance, which are the signs of toxicity that manifest as a
result of a gradual increase in the dose of the test substance.
Certain drawbacks to animal testing however do exist; the costs of the animals to be used
can be prohibitive and subtle differences within species can affect the type of effects that are
observed and they are usually more tedious to arrange, in terms of duration of experiments.
4. General tests
Standard guidelines for the conduct of animal toxicity tests have been harmonized by the
Organization for Economic Co-operation and Development [76] as part of continuous efforts
to internationally harmonize test guidelines.
Before conducting safety study of an herb or its product in animals, some major factors that
need to be considered are:
Preparation of test substane: Herbal products can be prepared into different dosage forms
like capsules, tablets, ointments, creams and pastes. For correct administration of a pre-de‐
fined dose of the product, the product should be quantitatively standardized and adminis‐
tered based on its intended use in humans.
Animal  welfare  considerations:  Guidance  on  the  use  of  clinical  signs  as  humane  end‐
points for experimental  animals used in safety evaluation [77] have been reviewed else‐
where  and  the  reader  is  advised  to  look  it  up.  In  particular  paragraph  62  of  the
guideline thereof,  should always be followed.  This  paragraph states  that  “In studies in‐
volving repeated dosing, when an animal shows clinical signs that are progressive, lead‐
ing  to  further  deterioration  in  condition,  an  informed decision  as  to  whether  or  not  to
humanely kill  the animal should be made. The decision should include consideration as
to the value of the information to be gained from the continued maintenance of that ani‐
mal on study relative to its  overall  condition.  If  a  decision is  made to leave the animal
on  test,  the  frequency  of  observations  should  be  increased,  as  needed.  It  may  also  be
possible,  without adversely affecting the purpose of the test,  to temporarily stop dosing
if it will relieve the pain or distress, or reduce the test dose.”
Animals: Different rodent and non-rodent species are used in animal toxicity tests. In chron‐
ic studies, justification is often required for choice of specie or strain of animals used. All an‐
imals should be housed in acceptable environmental conditions and adequately catered for
in accordance with stipulated guidelines [78].
New Insights into Toxicity and Drug Testing74
Regulatory requirements: An independent animal ethics committee usually reviews, appro‐
ves and supervises animal experiments and ensures that the experiment is well justified and
in agreement with provisions for animal welfare. These regulations may differ, dependin‐
gon different countries, but basic requirements to be met remain unchanged.
4.1. Acute systemic toxicity
This test measures relative toxicological response of an experimental organism to single or
brief exposure to a test substance [79]. Test organisms range from simple systems like brine
shrimp to other animals like mice, rats, guinea pigs and rabbits. This test is also used to calcu‐
late median lethal dose (LD50) of a substance, using various standardised methods including
Lorke’s and acute toxic class methods [79, 80]. Exposure routes may be by oral gavage, inhala‐
tion/mucosal, dermal; or by injection into the bloodstream, abdomen, or the muscles. Follow‐
ing administration of a test product, animals are observed individually at least once during the
first 30 minutes, periodically during the first 24 hours, with special attention given during the
first 4 hours, and daily thereafter, for a total of 14 days in the case of delayed toxicities [79]
4.2. Sub-acute/sub-chronic toxicity
This is repeat-dose study performed to expose any deleterious changes in organ, haemato‐
logical and biochemical indices that may arise in the course of repeated administration of a
test substance, usually ranges from weeks to a few months. The terms ‘sub-acute’ toxicity
and ‘sub chronic’ toxicity can be differentiated on the basis of exposure, the former having a
duration period of one month (28-30 days) and the latter ranging from two to three months
(60-90 days). The test product or compound is usually administered daily throughout the
test period and at the end of the study, data generated will include general parameters such
as daily food consumption and water intake measurements and body weight measurements.
Other specific endpoints of toxicity assessed will additionally include serum biochemical pa‐
rameters (Lipid, protein, urea, creatinine, electrolytes, liver transaminases and phosphatase),
enzymatic and non-enzymatic liver oxidative stress indicators (thiobarbituric acid reactive
substances, reduced glutathione, catalase) and haematological parameters (white blood cells
and differentials, red blood cells, haemoglobin, haematocrit, platelets, lymphocytes). Vari‐
ous organs are examined for gross pathological changes and tissue slices obtained from re‐
spective organs are prepared for detailed histological examination.
Results of many sub chronic toxicity tests of various plant extracts showed that the major
organs usually affected are the liver and kidneys. Hepatotoxic and nephrotoxic effects are
mostly to be expected, as the liver acts as the main detoxifying organ for chemical substan‐
ces, while the kidney is a principal route of excretion for many chemical substances in their
active and/or inactive forms [81].
Liver injury associated with the use of herbal medicine ranges from mild elevation of liver
enzymes to fulminant liver failure often requiring a new transplant; and carcinogenesis [63].
Established hepatotoxic phytochemicals include podophyllin, eugenol, neoclerodane diter‐
penes, among others [83-88].
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 Figure 5. Clockwise from top left: Photomicrographs (×400) of kidney tissue slices from rats treated with (a) aqueous vehi‐
cle, (b) 25, (c) 50 and (d) 100 mgkg-1 body weight Hymenocardia acida ethanol leaf extract. Fig. 5a shows normal tubular
architecture while Fig. 5b, c and d show alterations ranging from mild cortical oedema to tubular distortions. [82].
5. Chronic toxicity/carcinogenity
Chronic toxicity testing is similar to sub chronic studies except that they are conducted with
a larger number of animals to reveal toxicity which may arise during exposure to a sub‐
stance for a 24 months or for an entire lifespan. Oral, dermal or inhalation are the main
routes used here, depending on the intended use in humans. In these long-term studies, mu‐
tagenic/carcinogenic propensities of test substances and likely organs where they may accu‐
mulate are revealed. End points of toxicity which are studied include dose limits of toxicity,
that is, the lowest dose at which no toxicity occurs or no observed adverse effect level
(NOAEL), mortality, food consumotion, water intake, hematology and clinical biochemistry
measurement, organ gross necropsy ang histopathology. Further informmation on study de‐
sign and execution can be found in OECD draft guidance document on the design and con‐
duct of chronic toxicity and carcinogenicity studies [89].
5.1. Specialized tests
These are tests suited to reveal specific toxicities, such as reproductive toxicity, developmen‐
tal toxicity, eye and skin irritancy test (Draize test), neurotoxicity and Genotoxicity.
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Ocular/Skin irritancy test:
Named after a US food and Drug Scientist, John Draize, this test was developed in the mid-
nineteenth century. Eye and skin irritancy tests involve the topical application of the test
substance; usually in rabbit cornea or skin. Irritancy is reversible in nature and distinguish‐
ed from corrosion which is irreversible. This test has become unpopular due in part to the
percieved cruelty to the rabbit its very subjective scoring system, leading to poor reproduci‐
bility and high variablility between laboratories [90]. A recently developed short term expo‐
sure test using Statens Seruminstitut Rabbit Cornea (SIRC) cells has been demonstrated to
be a potential alternative for eye irritancy test in rabbits [91].
Neurotoxicity:
Neurological effects such as convulsions may arise followed acute systemic exposure to
some phytomedicines; while cerebrovascular accident, encephalopathy and psychosis can
become evident in sub acute, sub chronic and chronic tests for toxicity. It is important to
note that the presence of high levels of metals in the herbal medicine can contribute to neu‐
rotoxicity [92]. Microbial biosorptive removal using granulated Cladosporum cladosporioides
and chelation with dithizone have been shown to be effective in removing heavy metal con‐
taminants from herbal extracts [93, 94].
Genotoxicity:
Genotoxicity is a special area in toxicities, as it is often the most difficult to detect. It may be
defined as a chemically induced mutation or alteration of the structure and/or segregation of
genetic material.Recently, a guidance document on the assessment of genotoxcicity of herbal
preparations has been drafted by the European Medicines Agency [95]. The first stage uti‐
lizes the Ames test with S. typhimurium, although some potent genotoxins like Taxol (Taxus
brevifolia) and vincristine (Catharanthus roseaus) are not reliably identified at this stage and
some products rich in flavonoids like quercetin may give false positives. More reliable tests
like the mouse micronucleus test and mouse lymphoma assay (MLA) can be used more de‐
finitively [95].
Reproductive/developmental toxicity studies:
These studies were developed after it was discovered thousands of offspring of women who
used the new drug thalidomide to treat morning sickness were born with serious birth de‐
fects [96]. It was later proposed that the drug acts by decreasing transcription efficiency of
the genes responsible for angiogenesis in the developing limb bud of the foetus, resulting in
truncation of the limb [97]. In designing these tests, a large number of animals are used,
which are dosed repeatedly with escalating doses of the herbal test substance before mating,
during gestation and after delivery up to the entire lifetime of the new offspring to detect
effects of the herb on reproductive performance and/or developing offspring. Toxicity end‐
points include spontaneous abortion, premature delivery, and birth defects.
In addition to the use of rodents, research in reproductive and developmental toxicity of tra‐
ditional Chinese medicine incorporates other animal models like zebrafish and roundworm
models and stem cell cultures [98].
Screening of Herbal Medicines for Potential Toxicities
http://dx.doi.org/10.5772/54493
77
5.2. Clinical testing: Clinical/safety trials
After sufficient preliminary investigation showing the safety of an herbal product in pre-
clinical studies, further studies can then be initiated in human participants. These type of
studies are called clinical trials (CTs) and are carried out in four phases, I – IV [99].
Phase  I:  These  are  CTs that  are  specially  designed with a  minimum number  of  human
participants  that  voluntarily  consent  to  partake  in  assessing  the  impact  of  use  of  the
herbal  product  on  vital  physiological  indices.  It  is  the  usually  the  first  stage  of  testing
in  healthy  humans  to  determine  the  safety  and maximum tolerable  doses  of  the  inves‐
tigational  substance  before  any further  human testing  may be  carried out.  It  is  howev‐
er  acceptable  that  for  certain  herbs  with  long  history  of  use,  this  phase  may  be
unecessary [99]
Phase II: Studies carried on a limited number of participants to determine clinical efficacy,
also labelled as feasibility studies. In this study, doses that are observed to be relatively safe
are used, participants are also monitored for the occurence of adverse effects [99].
Phase  III:  In  this  phase,  a  larger  number  of  participants  is  used  in  different  centres
and the study is  designed as  a  randomized,  double-blind,  controlled CT.  It  is  a  valida‐
tory  study  for  clinical  efficacy  of  the  herbal  product,  usually  compared  with  a  stand‐
ard intervention [99].
Phase IV/post-marketing surveilance: Monitoring for rare side effects which may have been
unnoticed during Phases I – III but may occur after the product has been introduced to the
market [100].
There are critical issues which must be considered to provide justification for the clinical tri‐
al of herbal products and guidelines to this effect have been provided by the World Health
Organization [99]. These areas of consideration are listed below:
Chemistry-manufacturing-control:  Unlike  conventional  medicines,  herbal  medicines  are
frequently monoherbal or polyherbal with wide chemical composition. While it is not re‐
quired for an active compound to be isolated as it is accepted that the action of the com‐
pounds in the product may be synergistic, a means of standardisation has to be used for
the  product  that  would be  representative  of  the  final  product.  If  the  active  principle  is
known,  it  can  serve  as  the  marker  for  the  product.  If  unknown,  a  chemical  marker  of
sufficient  quantity  or  a  chemical  fingerprint  of  the  entire  product  can  be  used,  within
specified limits. Preparation of the herbal medicine intended for administration in a clini‐
cal trial also has to be carried out in accordane with WHO guidelines on good manufac‐
turing practices for herbal medicines [101].
Provision of information on the herbal substance and the herbal product is also an impor‐
tant requirement. This includes a description of the source of the plant and its processing,
storage conditions and shelf life. Information regarding the product including excepients,
dosage form, analytical parameters for active compound or chemical markers, storage con‐
ditions over the lenght of the trial and specifications that would be assessed before clinical
trial material is released will also need to be furnished.
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Non-clinical considerations: This constitutes a supportive background upon which a clinical
investigation is based. In general, data on efficacy, toxicity and pharmacokinetics which
have been demonstrated or obtained from appropriate literature sources including journal
publications and reference pharmacopoiea. A systematic review of earlier trials of the same
herb or a related one can be done where possible in order to identify gaps that can be bridg‐
ed in the proposed trial.
Clinical considerations: At all stages of the trial, ethical standards and quality requirements
have to be met. For a phase 1 safety study, the adverse effects related to increasing doses of the
test product are observed in human participants recruited within the limits of inclusion based
on gender, weight, age and health status. An outline of the basic safety parameters that are
monitored are shown in Table 2. The standard intervention is usually the product itself. The
study may be randomized, blinded, double blinded or placebo-controlled to minimize bias.
Ethical considerations: All CT protocols require approval by regional ethical board before
such trials can be executed. All research that involves human participation, including clini‐
cal trials must apply fundamental thical principles and must adhere to standards of good
clinical practice [102]. Informed consent of all participants or gaurdians of minor partici‐
pants must be obtained. It is required that each participant is well informed of any concerns
regarding the trial herbal product especially with respect to rarely understood interactions,
or known undesirable effects. Risks to participants must be minimized and as such, experi‐
enced ethical investigators including clinicians who can promptly identify and treat ob‐
served adverse events in participants need to be involved as CT investigators.
Organ/system
Neurological:
Safety parameter
lack of neurologic symptoms
Musculoskeletal: lack of arthritis or myalgias, normal values of CPK
Skin: clinical evidence of lack of allergic reactions
Gastrointestinal: clinical evidence of tolerability
Liver: normal values of SGOT or SGPT, alkaline
phosphatase, total bilirubin,
Kidney: normal values of BUN or creatinine
Endocrine system and metabolism: normal values of albumin or total protein, uric acid, glucose,
cholesterol, amylase or lipase,
sodium/potassium, calcium
Cardiovascular: normal EKG and blood pressure
Haematopoietic: normal values of complete blood count
Additionally: more intensive investigation of any organ system likely to be
affected by the product
Table 2. Basic physiological parameters monitored in phase 1 clinical trial [99]
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6. Conclusions and perspectives
Summarily, the processes involved in the toxicological evaluation of complex herbal ex‐
tracts/mixtures and chemically characterized isolated compounds are schematically repre‐
sented below. It is noteworthy that currently, only chemically characterized phyto
compounds are useful candidates for QSAR studies and high throughput toxicogenomic as‐
says, as compound data libraries exists for data comparison.
 
Herbal Medicinal 
Product 
High throughput 
toxicogenomic studies, 
microarrays, 
proteomics, 
metabonomics 
Animal studies: 
Acute, sub-chronic, 
chronic toxicity 
other tests 
QSAR, ADMET modeling 
and simulation 
Metabolic studies with 
human microsomal CytP450 
Cytotoxicity assays: cells of 
primary origin, e.g. rat 
fibroblasts, SHE cells; 
permanent cell lines (THP1, 
HeLa, MCF7, HepG2) 
Phase IV /  
Pharmacovigilance 
Pure 
Chemical 
Molecule 
Phase I 
Clinical 
Studies 
Phase II  
Trials 
Phase III  
Trials 
Bioactivity guided 
isolation, chemical 
characterization 
Comparison of 
compound profile with 
xenobiotic data libraries 
Figure 6. Schematic processes involved in evaluating and establishing the toxicity of medicinal herbs. The broken ar‐
row indicates that for some herbal medicines, phase 1 clinical trials may not always be necessary.
Toxicity testing of herbal medicines in the 21st century tends to begin in a reductionist man‐
ner and proceeds through holistic tests to reach clinical conclusions. The challenge however,
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remains the identification of unique approaches in testing and developing regulations re‐
garding safety of herbal products. Although some drawbacks to animal testing exists; such
as the large number of animals used, financial implications and poor validation which af‐
fects correlation to humans, animal testing is still relevant as it is still impossible to predict
long term carcinogenicity, embryotoxicity and reproductive toxicity using alternative non-
animal tests alone.
A major issue in toxicity testing is “Animal welfare”. The use of animals in research gave
rise to the adoption of the critical 3 R’s to consider before conducting animal-based toxicity
testing of herbals. This calls for a fundamental paradigm in regulatory toxicology; there is a
need to reduce the number of animals, refine the tests methods used in order to minimize
pain and suffering of experimental animals, and replace animal tests with validated alterna‐
tives employing human cells where possible. Some instances of efforts in this regard are the
development of a transcriptomics based in vitro screening method to predict embryotoxicity
using the embryonic stem cell test. Additionally, the number of rats used for LD50 tests can
be significantly reduced by the adoption of in vitro cell-based assays and chemicals shown to
be harmful to cultured cells are excluded from any further LD50 tests and animal tests. It is
no longer news that, cellular models of toxicity are more rapid and can easily be adapted to
high throughput screening.
Next generation sequencing technology and toxicogenomics are strong predictive tools but
databases of genetic biomarkers of toxicity of herbal medicines need to be enriched. It will
be worthwhile to develop data libraries upon which prediction of the safety herbal extracts
can be done to fully exploit these screening tools. As pointed out earlier, this can be ach‐
ieved by creating genomic signatures of identified phytochemicals which can serve as data
library for herbals.
Standardization of an herbal product in terms of parts per million limits of heavy metals
will also eliminate product contamination and its associated toxicity. Chemical standardiza‐
tion of medicinal herbs with High Pressure Liquid Chromatography (HPLC) alone or hy‐
phenated with Mass Spectroscopy (HPLC-MS) or Nuclear Mass Resonance Spectroscopy
(HPLC-NMR) would also ensure chemical uniformity and detect chemical adulterants in
herbal products.
More so, the integration of recent biotechnological innovations like computer-aided model‐
ing and simulation studies, bioinformatics, high throughput screens, toxicokinetic and toxi‐
cogenomic tools in a systems toxicology approach with other necessary tests in experimental
animals and appropriately designed clinical observation studies will undoubtedly bring
about significant advances in predicting and determining herbal medicine safety.
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